Objective: To determine whether family history of coronary heart disease (FH) definitions differ in their association with atherosclerotic cardiovascular disease (ASCVD) events. Patients and Methods: Participants who provided FH data from July 17, 2000, through February 24, 2004, were identified. Definitions of FH were any, premature, and Familial Risk Assessment (FRA). Outcomes included coronary heart disease (CHD), stroke, peripheral artery disease, angina, and congestive heart failure. Multivariable-adjusted Cox models examined the association of FH definitions with events. C statistics and the net reclassification index examined the incremental prognostic contribution of each definition. Results: In 6200 participants, the proportions of any FH and premature FH were 36% and 16%, respectively, and of weak, moderate, and strong familial risk were 20%, 16%, and 20%, respectively. Over median follow-up of 10.1 years (range, 0.02-11.5 years), 741 participants experienced a composite event. Compared with no FH, any FH was associated with incident CHD, angina, and composite ASCVD (hazard ratios [95% CIs]: 1.4 [1.1-1.8], 1.6 [1.2-2.1], and 1.3 [1.1-1.5], respectively). Similar results were obtained for premature FH compared with no FH and for strong compared with weak FRA for these 3 outcomes. There was no association between the FH definitions and noncoronary cardiovascular events. Compared with traditional risk factors (C statistic ¼ 0.740), any FH, premature FH, and FRA all improved discrimination of composite ASCVD (all P < .01); however, the differences in C statistics among any FH (0.743), premature FH (0.742), and FRA (0.744) were numerically small, as were differences in the net reclassification index. Conclusion: A single question regarding the presence of FH in any first-degree relative performs just as well as more complicated assessments in predicting CHD. Trial Registration: clinicaltrials.gov Identifier: NCT00005487.
P rimary prevention of atherosclerotic cardiovascular disease (ASCVD) is based on the accurate identification of adults who will benefit from lifestyle and pharmacologic interventions that are aimed at risk reduction. In this context, the collection of information regarding family history of coronary heart disease (FH) may represent an inexpensive and evidence-based tool to improve the assessment of ASCVD risk and guide preventive therapies. 1 Current guidelines recommend considering the presence of premature coronary heart disease (CHD) when the decision to initiate pharmacologic therapy remains uncertain after considering other risk factors. 2 However, the collection and assessment of familial risk is often not performed in routine clinical practice, and when it is, providers differ in how much detail they obtain. 3 Although FH is an established risk factor for developing future ASCVD events, previous studies have differed widely in the applied definition of FH, have been racially homogenous, have not considered sex differences, or have exclusively evaluated CHD or stroke as the ASCVD end point. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Possibly resulting in part from these limitations, minimal prognostic discrimination is typically seen with the addition of FH to models containing traditional risk factors. [5] [6] [7] 14 For this reason, information on FH is not included in standard ASCVD risk equations, such as the Framingham risk score (FRS) or the pooled cohort equations (PCE). 2, 15 Given these considerations, further characterization of the association between various definitions of FH and ASCVD in an ethnically diverse population could provide stronger evidence for the routine incorporation of FH assessment into primary prevention efforts. We also hypothesized that FH definitions may differ in their association with various ASCVD outcomes over extended 10-year follow-up.
METHODS

Study Population and Data Collection
The Multi-Ethnic Study of Atherosclerosis (MESA) recruited 6814 participants between 2000 and 2002 across 6 field centers, with full details previously published. 16 Participants were aged 45 to 84 years; identified their race/ ethnicity as white, black, Hispanic, or Chinese American; and were free of clinical ASCVD at baseline. Data pertaining to FH were obtained at the baseline visit (July 17, 2000, through September 5, 2002) and at visit 2 (September 9, 2002, through February 24, 2004 ). As such, only persons who attended both visits (n ¼ 6201) were included. Overall, the final analysis consisted of 6200 participants, with 1 person excluded due to unavailable FH data. Institutional review boards at each site approved the study, and all the participants gave written informed consent.
At the baseline visit, demographic information, medical history, anthropometric measurements, and laboratory data were collected. Body mass index was calculated as the weight in kilograms divided by the height in meters squared. High-density lipoprotein cholesterol (HDL-C) level was measured using the cholesterol oxidase method. Low-density lipoproteincholesterol (LDL-C) level was calculated using the Friedewald equation. 17 Diabetes mellitus (DM) was defined as the use of insulin or oral hypoglycemic medications or a fasting glucose level of 126 mg/dL or greater (to convert to mmol/L, multiply by 0.0555). 18 Hypertension was defined as a history of physiciandiagnosed hypertension, taking a medication for hypertension, a systolic blood pressure (BP) of 140 mm Hg or greater, or a diastolic BP of 90 mm Hg or greater. 19 Study participants also self-reported personal habits, such as alcohol and current tobacco use (defined as having smoked a cigarette in the past 30 days and >100 cigarettes in a lifetime).
Family History Assessment
At baseline (visit 1), participants reported on the presence or absence of an FH of heart attack or stroke in any first-degree relative: mother, father, siblings, or child. Response options were "yes," "no," and "do not know." At visit 2, participants were asked if any relative had CHD, stroke or cerebral hemorrhage, or DM, with response options the same as those at visit 1. If a participant reported a disease in a relative, the age at diagnosis was ascertained. For the purposes of this analysis, "do not know" responses were counted as "no" responses.
We defined "any FH" as CHD occurring in a first-degree relative, irrespective of age, and "premature FH" as having at least 1 relative with CHD occurring before age 55 years in men and 65 years in women. We also used the validated Familial Risk Assessment (FRA) tool to categorize FH risk as strong, moderate, or weak. The FRA is based on the number, sex, lineage, and age at onset of relatives with CHD, stroke, and DM (Table 1) . 20, 21 Ascertainment of Incident ASCVD A detailed description of the event adjudication process in MESA has been previously published. 22 We analyzed 5 separate clinical end points. First, hard CHD: defined as myocardial infarction, resuscitated cardiac arrest, or CHD death. Second, angina: defined as definite, probable, or absent. For definite or probable angina, participants were required to have physician-diagnosed typical or atypical symptoms of chest pain. Definite angina further required a history of a coronary artery bypass graft or revascularization procedure, at least 70% obstruction on angiography, or evidence of ischemia by stress testing or resting electrocardiography. 23, 24 Third, stroke: defined as fatal or nonfatal due to hemorrhage or infarct. Fourth, peripheral artery disease (PAD): defined as an ankle-brachial index value of less than 0.9 and did not require symptoms. 25 Fifth, congestive heart failure (CHF): defined as having shortness of breath or peripheral edema, plus pulmonary edema by chest radiography, or dilated ventricle or poor left ventricular function by echocardiography or ventriculography, or evidence of left ventricular diastolic dysfunction. 26 
Statistical Analyses
Baseline characteristics of the study participants in each of the FH status groups (none, any, and premature) and for each of the FRA categories (weak, moderate, and strong) were compared using analysis of variance for continuous variables and the c 2 test for categorical variables.
We used Cox proportional hazards regression models to study the association of FH status and outcomes. The proportionality assumption was tested and satisfied using graphical methods (log-log plots). Models were adjusted for age, sex, race/ethnicity, education, MESA site, body mass index, cigarette smoking, systolic BP, LDL-C, HDL-C, antihypertensive medication use, and lipid-lowering therapy. We also tested for multiplicative interaction between FH status and either sex or race/ethnicity in the association with ASCVD risk.
Area under the receiver operating characteristic curve was used to assess discrimination of ASCVD events. The likelihood ratio test examined the improvement in discrimination when FH information was added to variables included in the 2013 PCE for ASCVD risk estimate (age, sex, race/ethnicity, systolic BP, treatment for hypertension, HDL-C level, total cholesterol level, DM, and smoking). The net reclassification index (NRI) was used to assess Familial risk stratification rules were considered the presence of CHD, stroke, and diabetes in first-degree relatives. Information regarding second-degree relatives was not collected, although this information may have contributed further to the risk stratification. Early-onset CHD was defined as occurring before age 65 years in women and before age 55 years in men. Early-onset stroke was defined as occurring before age 50 years in both women and men. Neither CHD nor stroke occurring before age 25 years was considered because we suspected that these were most likely cases of congenital or hereditary forms of cardiovascular disease. Neither CHD nor stroke after age 85 years was considered. From the same lineage refers to maternal (mother and siblings or children), paternal (father and siblings or children), or nuclear (siblings or children) lineage.
the incremental contribution of FH information for reclassification of ASCVD events when added to categories of the FRS (calibrated for individual ASCVD outcomes) plus race/ethnicity. 27 In a sensitivity analysis, we assessed the incremental contribution of traditional risk factor elements of the FRS for ASCVD reclassification when added to baseline models containing the various FH definitions plus race/ethnicity. In addition, we calculated the same NRI analyses in only those categorized as intermediate risk by the FRS. Last, we used Cox proportional hazards regression models to study the association of the number of relatives with any FH and premature FH and composite ASCVD events, respectively. All the statistical analyses were performed using Stata software, version 13 (StataCorp). A 2-tailed P < .05 was considered statistically significant.
RESULTS
The study population consisted of 6200 individuals (mean AE SD age, 62 AE 10 years; 48% men and 40% white race). Overall, 36% (n ¼ 2211) and 16% (n ¼ 983) of MESA participants reported any FH or premature FH, respectively. The corresponding proportions for weak, moderate, and strong FRA were 20%, 16%, and 20%, respectively (Supplemental Table 1 , available online at http://www. mayoclinicproceedings.org). Compared with no FH, the any FH group had a higher percentage of individuals who were of white race, overweight, current smokers, and receiving BP and lipid-lowering therapy (Table 2 ). In the premature FH group, a higher percentage of individuals were younger, female, black or Hispanic race/ethnicity, overweight, current smokers, and receiving therapy for BP and lipid management. When stratified by FRA, the strong FH group had a higher percentage of individuals who were female, of black race, diabetic, and receiving therapy for BP and lipid management (Supplemental Table 1 ).
After a median of 10.1 years of follow-up (range, 0.02-11.5 years), 741 composite ASCVD events occurred overall (not accounting for repeated events occurring after the first occurrence of any of the individual components of the composite in a given participant) (Supplemental Table 2 , available online at http://www.mayoclinicproceedings.org). For individual outcomes, there were 250 CHD, 258 angina pectoris, 150 stroke, 75 PAD, and 206 CHF events. In those with any FH and premature FH, 317 and 142 composite events, respectively, occurred, representing cumulative incidences of 14% and 14%, respectively (see Supplemental Table 2 for individual outcomes).
In unadjusted analyses, point estimates for incident event rates (IRs) (per 1000 person-years) for composite and individual outcomes were qualitatively similar between any FH and premature FH (Supplemental Table 2 ).
FH Status and ASCVD Risk
Adjusted HR Based on Any FH. Relative to persons without an FH, any FH was significantly associated with composite ASCVD, hard CHD, and angina in all the models (Table 3) . No significant associations were found for stroke, PAD, or CHF (Supplemental Table 3 Adjusted HR Based on Premature FH. Among those who reported a premature FH (compared with no FH), significant associations were seen with composite ASCVD and angina in all the models (Table 3) . No significant association was found between premature FH and incident CHD. Similar to any FH, no significant association was found with any of the noncoronary cardiovascular events (Supplemental Table 3 and either ethnicity or sex in the association of composite ASCVD, CHD, and angina (data not shown).
Adjusted HR Based on Number of Relatives with FH. Among those who reported any FH, similar significant associations were seen with composite ASCVD when 1 or multiple relatives were affected (Supplemental Table 4 , available online at http://www.mayoclinicproceedings. org). Among those who reported a premature FH, the presence of multiple affected relatives predicted composite ASCVD events.
FRA and ASCVD Risk
When participants were stratified by the FRA, a significant graded relationship was seen for crude IR of the composite ASCVD outcome, hard CHD, and angina ( Figure 1 ). For example, the highest IR for the composite outcome was in those with a strong FH (16.6 per 1000 person-years). In addition, the highest IRs were found in outcomes for CHD and angina in those with a strong FH: 5.1 and 6.6 per 1000 person-years, respectively. Relative to a weak FH, a strong FH by the FRA was associated with composite ASCVD, CHD, and angina in all the models (Table 3) . For moderate FRA, associations were seen in demographic-adjusted models for composite ASCVD, CHD, and angina; however, this relationship persisted only for CHD after risk factor adjustment. Similar to FH status, none of the FRA categories were significantly associated with noncoronary cardiovascular events in all the models. Furthermore, there was no significant interaction for any event between FRA and either race/ethnicity or sex (data not shown).
In a sensitivity analysis, we repeated the models reported previously herein for each of the 3 FH definitions after stratification by whether the source of the FH was a sibling, parent, child, or spouse (the latter was used only in the FRA analyses). These models demonstrated qualitatively similar findings, although having a child or parent with an FH (any and premature) seemed to indicate a higher risk of composite ASCVD and angina (Supplemental Table 5 , available online at http://www.mayoclinicproceedings.org).
Addition of FH Status and FRA for the Discrimination of CHD and Composite ASCVD Events
For CHD events, the addition of FH status to the base model comprising traditional risk factors led to an increase in the C statistic from 0.736 to 0.738 (P ¼ .02) for any FH and from 0.736 to 0.737 for premature FH (P ¼ .09) (Figure 2A ). The FRA also improved the C statistic from 0.736 to 0.739 (P ¼ .05) when added to the base model.
For composite ASCVD events, the addition of FH status to the base model comprising traditional risk factors led to an increase in the C statistic from 0.740 to 0.743 (P < .001) for any FH and from 0.740 to 0.742 for premature FH (P < .05) ( Figure 2B ). The FRA also improved the C statistic from 0.740 to 0.744 (P ¼ .001) when added to the base model and provided further discrimination over and above premature FH status for composite ASCVD (C statistic from 0.742 to 0.744; P ¼ .05). Table 6 , available online at http://www.mayoclinicproceedings. org), the addition of Framingham risk factors to a base model that includes each FH definition resulted in a significant and larger NRI for incident CHD and ASCVD events in the total population and among those at intermediate risk by the FRS.
Reclassification Based on FH Status and FRA
DISCUSSION
In this contemporary, multiethnic cohort, FH definitions of differing complexity were all demonstrated to be independent risk factors for ASCVD events. Interestingly, the magnitude of these associations was similar for each FH definition. Although statistically significant, the incremental prognostic contribution to the C statistic for ASCVD was qualitatively similar for each FH definition. The association of FH and events was limited to CHD and angina, and other noncoronary cardiovascular outcomes were not statistically significantly associated. As such, our main finding is that all the approaches to defining FH considered in this analysis seemed to perform similarly in improving CHD risk prediction, supporting the use of a simple and practical approach to defining FH in routine clinical practice toward CHD prevention.
The comparison between simple and other more comprehensive assessments of FH has been described in other populations. [28] [29] [30] [31] However, comparisons between studies can be challenging given the different definitions of FH used, variable study designs, and duration of follow-up. For example, odds ratios have been reported from cross-sectional and retrospective studies for the association between premature FH (applying various definitions) and CHD ranging from 1.4 to 5.9. 5, 10, 11, 13, 30, 31 This study has a lower (and perhaps more valid) risk ratio for any FH or premature FH (both risk ratios were 1.3) given its prospective nature. 32 Consistent with this, the association of FH with CHD in the present study is similar in magnitude to other prospective studies, which reported HRs ranging from 1.3 to 1.7.
8,9
Adoption of FH into risk prediction models has been limited because (1) FH risk is often not independent of other established risk factors, (2) FH is nonmodifiable, and (3) the temporal association is varied between FH and ASCVD events (ie, a greater influence of shared, genetic component for premature events and a more balanced contribution of environmental and acquired CVD risk factors for later-onset events). 4, 8, [33] [34] [35] Indeed, traditional risk factors account for most of the attributable CHD risk, with only 1% contributed by FH, which provides a plausible explanation for the limited improvement in discrimination and reclassification with FH seen in the present study. 35 Despite these limitations, current guidelines recommend that clinicians assess premature FH status, particularly among intermediaterisk individuals, to potentially reclassify risk. 2, 36 However, some providers may be dissuaded from querying FH status given time constraints and the perceived complexity and unreliability of premature FH assessment. 3 Given the present results and the historical challenges of implementing FH information into risk assessment tools, it may be reasonable to consider using a simple definition of any FH to identify individuals at increased risk for CHD both in clinical practice and for research purposes.
Notably, the application of these results is most valid in the routine care of patients drawn from the general community (like MESA participants) when traditional risk factors are already known and CHD is the outcome of primary interest. We are unable to speculate whether detailed FH assessments may have added value at the individual treatment level in high-risk subsamples of the population. 37 For example, by incorporating the FRA, the Family Healthware tool accounts for the number, sex, age at onset, and lineage of relatives with CHD, with classification into 3 risk categories, and has been developed by the Centers for Disease Control and Prevention. 38 This MESA study cannot rule out that more detailed FH tools, such as the FRA, have value in some high-risk pedigrees. For example, we found that the number of relatives with premature FH (a form of high-risk pedigree) was incrementally associated with outcomes in this analysis, a situation in which these more detailed tools may have value. In addition, depending on the definition used, a vastly different number of patients could fall into different categories of risk. This has implications when considering how the FH assessment may change the care being offered to a given patient. For example, recent Society of Cardiovascular Computed Tomography guidelines recommend coronary artery calcium imaging if ASCVD risk by the PCE is less than 5% in patients with a premature FH. 39 However, many more people would have been eligible using the any FH definition. Thus, for certain applications that have cost or safety implications, an assessment of premature FH may be preferred.
The results of the present study should be interpreted in the context of several limitations. Self-reports of CHD in a first-degree relative are subject to high specificity and comparatively lower sensitivity, limiting accurate FH assessment by reporting errors. 40 Selection bias may have been introduced because detailed information on FH was collected at visit 2. As a result, participants who died of an ASCVDrelated event before visit 2 were excluded from the analysis. However, of those who did die (n ¼ 159), the proportion with any FH was statistically similar to the proportion of those with any FH included in the present analysis and the time between visits was short (median time, 1.6 years). 41 Given the number of ASCVD outcomes compared, multiple comparisons would have to be considered. Data collection may have been affected by recall bias (if participants were unable to accurately recollect the number of family members who had a CHD event) and by ascertainment bias related to the participant's age. Another limitation is the inclusion of persons responding "do not know" in the no FH group; however, we conducted a sensitivity analysis excluding such individuals from the analysis and the results were all quantitatively similar (data not shown). Our definition of PAD may not have allowed for an accurate assessment with various FH-phenotypes because the ankle-brachial index measurement is limited by noncompressible arteries, rendering it a sensitive but not specific test. 42 Given the age cutoff used for this study, the results may not be generalizable to those younger than 45 years who may have a strong premature FH.
CONCLUSION
Various definitions of FH can add significant prognostic information to traditional risk factors in the prediction of CHD events. Current prevention guidelines endorse the assessment of premature FH to guide ASCVD risk prevention, particularly when therapeutic uncertainty exists. Our MESA data would suggest that in aggregate and when other traditional risk factors are already known, a simple and singlequestion assessment of family history in a first-degree relative of any age may be more efficient and as effective as more complex FH definitions for identifying individuals with heightened CHD risk, a finding that should motivate more routine assessment of FH for ASCVD prevention in routine clinical practice.
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